Pyxis Oncology, Inc. (PYXS) company profile
Close on Nov 17, 2026Market cap $120.11MP/E –Yield –
About Pyxis Oncology
Pharmaceutical Preparations, SIC 2834
Pyxis Oncology is a clinical-stage biopharmaceutical company that develops targeted cancer therapies for individuals with difficult-to-treat solid tumors. The company focuses primarily on treating recurrent and metastatic head and neck squamous cell carcinoma. Its lead investigational product candidate is micvotabart pelidotin, an antibody-drug conjugate designed to target an extracellular matrix protein variant within tumor microenvironments. The company evaluates this drug candidate both as a single-agent monotherapy and in combination with other cancer immunotherapies across various solid tumor types, including breast, cervical, and gastric cancers. It also maintains technology platforms for antibody discovery and conjugate design. The target population consists of cancer patients with advanced solid malignancies who require further intervention after initial systemic therapies.
The company conducts clinical development activities internationally, maintaining clinical trial sites across the United States, the European Union, and several other countries. Its operations are driven by a multidisciplinary workforce covering research, clinical development, and corporate administration. The provided text does not state the location of the company's headquarters.
Summary of the business section of Pyxis Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pyxis Oncology, Inc.
- Founded
- 2018
- Headquarters
- Boston, MA
- Address
- 321 Harrison Avenue 02118
- Phone
- (617) 221-9059
- Website
- pyxisoncology.com
- Employees
- 56, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- PYXS
- Exchange
- Nasdaq
- IPO date
- Oct 8, 2021
- Shares outstanding
- 83M, Aug 12, 2026
- Public float
- $64.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1782223
- CUSIP
- 747324101
- ISIN
- US7473241013
- FIGI
- BBG00PQFFCV5
- Share class FIGI
- BBG00PQFFCW4
- EIN
- 83-1160910
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas Civik | CEO & Chairman of the Board, Director | 221,886 |
| Lara Sullivan | President ,CEO & CMO, Director | 2,403,882 |
| Jitendra Wadhane | Prin Fin & Acct Officer | 512,882 |
| Pamela Ann Connealy | CFO & COO | 3,425,179 |
| Rachel Humphrey | Director | 81,309 |
| Jakob Dupont | Director | 73,741 |
| Santhosh Palani | Director | 6,000 |
| Michael A. Metzger | Director | – |
| Freda C. Lewis-Hall | Director | 241,405 |
| John L. Flavin | Director | 413,015 |
| Darren S. Cline | Director | 251,405 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Lara Sullivan Former President, Chief Executive Officer and Chief Medical Officer | $646.88K | – | $723.08K | $291.09K | $10.50K | $1.67M | -76% |
| Jitendra Wadhane Principal Financial and Accounting Officer | $414.00K | – | $207.70K | $134.55K | $10.50K | $766.75K | – |
| Pamela Connealy Former Chief Financial Officer and Chief Operating Officer | $262.80K | $402.37K | $349.09K | – | $410.98K | $1.43M | -45% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 8, 2021
- Offer price
- $16.00
- Securities offered
- 10,500,000
- Gross proceeds
- $168.00M
- Exchange
- Nasdaq
- First trading day
- Oct 8, 2021
- First-day close
- $13.20-17.5%
- Lock-up ends (est.)
- Apr 6, 2022
“The initial public offering price of our common stock is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 20, 2026, we had 56 full-time permanent employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 23, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 8, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 8, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 5, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?